# Bharat Rasayan share price today (Bharat Rasayan Ltd, NSE: BHARATRAS)

> Bharat Rasayan share price today: ₹950.95 at the NSE close on 3 November 2026, down 64.9% in a year. Bharat Rasayan (NSE: BHARATRAS) is worth ₹1,580 crore, trades at a P/E of 10.8 and has closed between ₹931.80 and ₹2,744.25 over the past 52 weeks. > Bharat Rasayan Ltd's P/E is near the low end of its own history, higher than only 1% of past readings, and its quarterly results are still getting worse. BHARATRAS · Pesticides/Agrochemicals · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/bharat-rasayan-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: ₹950.95 (−64.9% in a year)
- P/E: 10.8× (lower than 99% of the last 6.3 years)
- Revenue (Jun 2026): ₹338 Cr (−10.3% on a year ago)
- Profit (Jun 2026): ₹37.0 Cr (−7.5% on a year ago)
- Operating margin: 15.0% (−3.0 points on a year ago)
- ROCE: 16%, FY26
- ROIC: 11.3%, against a 12.0% cost of capital: −0.7 points

The main question: yearly earnings per share moved +3.3% while the share price moved −64.9%. ## What is the Bharat Rasayan share price today? Bharat Rasayan Ltd's share price was ₹950.95 at the close on 3 November 2026. It has been falling for 44 weeks. That is 33.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹932 and ₹2,744, and at that close it sat 1% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 25 weeks running. Over the last 11 years the share price moved +337% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 10 June 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Bharat Rasayan this quarter? Three changes stood out: revenue fell in the June 2026 quarter, indian funds and insurers (DIIs) cut their stake for 4 quarters in a row and number of shareholders up 50% in a year. 1. Revenue fell in the June 2026 quarter Revenue was ₹338 crore, -10.3% on a year earlier (₹377 crore), after 2 quarters of growth. 2. Indian funds and insurers (DIIs) cut their stake for 4 quarters in a row From 2.8% to 1.7% of the company by the September 2026 quarter. 3. Number of shareholders up 50% in a year 23,084 shareholders in the September 2026 quarter, against 15,388 a year earlier. ## What are Bharat Rasayan's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Bharat Rasayan reported revenue of ₹338 crore, down 10.3% from ₹377 crore a year earlier, and a profit of ₹37.0 crore, down 7.5% from ₹40.0 crore. ### Bharat Rasayan results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹338 crore | ₹377 crore | −10.3% |
| Profit | ₹37.0 crore | ₹40.0 crore | −7.5% |
| Earnings per share | ₹22.40 | ₹23.89 | −6.2% |
| Operating margin | 15.0% | 18.0% | −3.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Bharat Rasayan share price history? Bharat Rasayan closed at ₹950.95 on 3 November 2026, down 64.9% from ₹2,712.75 a year earlier (31 October 2025) and down 63.0% over five years. Its highest weekly close since March 2016 was ₹3,520.72 on 22 April 2022. ### Bharat Rasayan share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹943.70 | +0.8% |
| 1 month ago · 1 Oct 2026 | ₹998.70 | −4.8% |
| 6 months ago · 30 Apr 2026 | ₹1,384.70 | −31.3% |
| 1 year ago · 31 Oct 2025 | ₹2,712.75 | −64.9% |
| 3 years ago · 3 Nov 2023 | ₹2,155.15 | −55.9% |
| 5 years ago · 4 Nov 2021 | ₹2,570.68 | −63.0% |
| 10 years ago · 4 Nov 2016 | ₹451.99 | +110.4% |
| Earliest and lowest weekly close in our records · 11 Mar 2016 | ₹217.57 | +337.1% |
| Highest weekly close since March 2016 · 22 Apr 2022 | ₹3,520.72 | −73.0% |
| 52-week high (weekly close) · 7 Nov 2025 | ₹2,744.25 | −65.3% |
| 52-week low (weekly close) · 30 Oct 2026 | ₹931.80 | +2.1% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Bharat Rasayan? 3 Nov 2026: Bharat Rasayan closed at ₹950.95, up 0.8% on the week and down 4.8% on the month. 17 Sep 2026: ex-date for a dividend of ₹0.50 a share. ### Earlier

- Results for April to June 2026: Revenue down 10.3% and profit down 7.5% on a year earlier. - 12 Dec 2025: Share split: face value cut from ₹10 to ₹5 a share (ex-date). - 12 Dec 2025: Bonus issue: 1 new share for every 1 held (ex-date). ## What dividend does Bharat Rasayan pay? Bharat Rasayan paid ₹0.50 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.05% at the ₹950.95 close on 3 November 2026. The last was a dividend of ₹0.50 a share, ex-date 17 September 2026. ### Bharat Rasayan dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 17 Sep 2026 | ₹0.50 | Dividend |
| 12 Sep 2025 | ₹1.50 | Dividend |
| 12 Sep 2024 | ₹1.50 | Dividend |
| 6 Sep 2023 | ₹1.50 | Dividend |
| 5 Sep 2022 | ₹1.50 | Dividend |
| 6 Sep 2021 | ₹1.50 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Bharat Rasayan Ltd paid out 1% of its profit as dividends in FY26, and it paid a dividend in 3 of its last 8 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Bharat Rasayan on? Bharat Rasayan is on one of our India lists: 52 week high & low. [52 week high & low 52-week position: At 52-week low](https://www.sectoralpha.in/52-week-high-stocks-india)

## Is Bharat Rasayan profitable? Bharat Rasayan Ltd earned ₹37.0 Cr of net profit in the Jun 2026 quarter, −7.5% on the same quarter a year earlier. Full-year FY26 profit was ₹146 Cr. Over 7 years profit has grown 3.9% a year on average. That is 10.9% of the quarter's revenue. The same quarter a year earlier earned ₹40.0 Cr. For the full year, FY26 profit was ₹146 Cr (+3.5% on the year before). Why profit moved: revenue changed −10.3% on a year earlier and the margin moved −3.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +7.4% and revenue −4.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Bharat Rasayan make, and is it growing? Bharat Rasayan Ltd reported ₹338 Cr of revenue in the Jun 2026 quarter, −10.3% on the same quarter a year earlier. Over 7 years it has grown 3.3% a year on average. The last full year, FY26, came in at ₹1,240 Cr. The last four reported quarters add to ₹1,202 Cr. FY26 revenue was ₹1,240 Cr, +5.9% on the year before. Recent pace: the last four quarters grew −4.3% on average, against 3.3% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −5.2%, against +5.1% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +3.6%, against +4.5% a year (stabilising). ## How much of every ₹100 of sales does Bharat Rasayan keep? Bharat Rasayan Ltd's operating margin was 15.0% in the Jun 2026 quarter, 3.0 percentage points lower than the same quarter a year ago. Across 8 years it has been between 11.0% and 22.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −3.3 percentage points on the year while gross margin changed −0.5 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Bharat Rasayan's profit turning into cash? Over the last 3 years, 90% of Bharat Rasayan Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹132 Cr of operating cash against ₹146 Cr of profit. After ₹73.0 Cr of spending on assets, ₹59.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 90% of profit came in as cash: the cash cycle got 63 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 1.7× depreciation over three years. The next section checks what that spending is building. ## Where does Bharat Rasayan's cash go? Bharat Rasayan Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 219 days in FY26, up from 156 days in FY21. It spent ₹135 Cr on assets over the last 3 years. Customers take 113 days to pay, and stock sits for 150 days on average. At FY26 sales of ₹1,240 Cr, each day of that cycle ties up about ₹3.4 Cr, so roughly ₹744 Cr is tied up in the business at any time. FY26: customers took 113 days to pay and stock sat for 150 days, about 4.9 months of sales sitting as stock, for a full cycle of 219 days, longer than FY21's 156. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 150 days. Customers pay about 113 days after that. Suppliers are paid at 44 days. Together that makes the 219-day cycle. Spending on assets: ₹135 Cr over the last 3 years, against ₹79.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹46.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Bharat Rasayan's P/E ratio, and how does it compare with its own history? Bharat Rasayan Ltd's P/E is 10.8×, about the lowest it has ever been. Its usual P/E (the middle reading) is 27.7×, over 6.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹86.23. Why the multiple is where it is: over the past year earnings per share moved +3.3% while the price moved −64.9%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved −18.0% a year; about −1.8% a year came from earnings growth and about −16.2 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Bharat Rasayan business getting better or worse? Bharat Rasayan Ltd's business is giving mixed signals. Eps growth is rising at +4.1% while revenue growth is falling at −5.2%, so the lines disagree and each one tells part of the story. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Bharat Rasayan earn on its capital? Bharat Rasayan Ltd earned a ROCE of 16% in FY26. That is up from a low of 12% in FY24. Its return on capital used (ROIC) is 0.7 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 11.8% net margin and 0.87× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 11.8% net margin × 0.87× asset turnover × 1.12× leverage (assets divided by equity) ≈ 11.5% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 11.3% − 12.0% = −0.7 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 11.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 13.7%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Bharat Rasayan have too much debt? Bharat Rasayan Ltd has total debt of ₹1.0 Cr against shareholder equity of ₹1,275 Cr as of Jun 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.23 in FY22 to 0.00 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Bharat Rasayan shareholding pattern? No group of Bharat Rasayan Ltd's owners changed its stake by a full percentage point over the last two years. Foreign institutions moved +0.1 points over the same period, to 0.6%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: −0.9 points over 8 quarters, to 1.7%; Foreign institutions: +0.1 points over 8 quarters, to 0.6%; Promoters: +0.0 points over 8 quarters, to 75.0%. ## How far is Bharat Rasayan from balance-sheet trouble? For Bharat Rasayan Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Bharat Rasayan rank in its industry? 45.3 out of 100, rank 14 of 25 in Pesticides/Agrochemicals, with 96% of the evidence available. Bharat Rasayan Ltd scores 45.3 out of 100 against the 25 companies it is compared with in Pesticides/Agrochemicals, ranking 14. The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. The four parts add up to the total exactly: 10 + 15.3 + 15.7 + 4.3 = 45.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Bharat Rasayan compared with? Bharat Rasayan ranks 14 of 25 Pesticides/Agrochemicals companies on the 4-Factor Sector Score, with 45.3 out of 100. 1. [Sharda Cropchem Ltd](https://www.sectoralpha.in/stocks/sharda-cropchem-ltd) SHARDACROP · basing · Most evidence points up · 100% evidence 71.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.5/35 · Revenue 17.3% · Profit 42.5% · Operating margin change 2 points · 100% evidence Capital efficiency 19.5/25 · ROCE 30.2% · Operating margin 16% · 100% evidence Valuation 19.2/20 · P/E 9.3× · PEG 0.3 · 100% evidence Relative strength 4.6/20 · Lead over its industry -14.3% · Lead over NIFTY 500 -22.1% · 1 year -23.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 28.5 + 19.5 + 19.2 + 4.6 = 71.8 · What this means: Earnings are strong; relative strength in its sector is -14.3% and the one-year return is -23.1%. 2. [Titan Biotech Ltd](https://www.sectoralpha.in/stocks/titan-biotech-ltd) turning · Most evidence points up · 83% evidence 70.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.1/35 · Revenue 31.8% · Profit 38.7% · Operating margin change 2 points · 83% evidence Capital efficiency 20.2/25 · ROCE 22.8% · Operating margin 21% · 95% evidence Valuation 5.4/20 · P/E 51.8× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 38.3% · Lead over NIFTY 500 25.1% · 1 year 101.5% · 100% evidence · 4 of 12 weeks ahead Exact sum: 28.1 + 20.2 + 5.4 + 16.7 = 70.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Bayer CropScience Ltd](https://www.sectoralpha.in/stocks/bayer-cropscience-ltd) BAYERCROP · quiet · Evidence leans up · 81% evidence 63.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.3/35 · Revenue -2.8% · Profit 23.8% · Operating margin change 2 points · 88% evidence Capital efficiency 19.6/25 · ROCE 29.1% · Operating margin 20% · 100% evidence Valuation 13.4/20 · P/E 20× · PEG 1.28 · 100% evidence Relative strength 8.6/20 · Lead over its industry n/a · Lead over NIFTY 500 -20.8% · 1 year -33.3% · 25% evidence · 0 of 12 weeks ahead Exact sum: 22.3 + 19.6 + 13.4 + 8.6 = 63.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Punjab Chemicals & Crop Protection Ltd](https://www.sectoralpha.in/stocks/punjab-chemicals-crop-protection-ltd) PUNJABCHEM · quiet · Evidence leans up · 81% evidence 63.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 8.2% · Profit 43.5% · Operating margin change 1 points · 88% evidence Capital efficiency 13.6/25 · ROCE 18.6% · Operating margin 12% · 100% evidence Valuation 15.9/20 · P/E 17.4× · PEG 0.33 · 100% evidence Relative strength 9.8/20 · Lead over its industry n/a · Lead over NIFTY 500 -9.4% · 1 year -36.4% · 25% evidence · 6 of 12 weeks ahead Exact sum: 24.3 + 13.6 + 15.9 + 9.8 = 63.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Dharmaj Crop Guard Ltd](https://www.sectoralpha.in/stocks/dharmaj-crop-guard-ltd) DHARMAJ · losing its lead · Evidence leans up · 81% evidence 63.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 8.7% · Profit 13.2% · Operating margin change 1 points · 88% evidence Capital efficiency 14.7/25 · ROCE 16.8% · Operating margin 15% · 100% evidence Valuation 17.5/20 · P/E 14.3× · PEG 0.38 · 100% evidence Relative strength 12.2/20 · Lead over its industry n/a · Lead over NIFTY 500 4.7% · 1 year -9.9% · 25% evidence · 3 of 12 weeks ahead Exact sum: 18.8 + 14.7 + 17.5 + 12.2 = 63.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [India Pesticides Ltd](https://www.sectoralpha.in/stocks/india-pesticides-ltd) IPL · quiet · Evidence leans up · 81% evidence 59.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.6/35 · Revenue 17% · Profit 10.1% · Operating margin change -2 points · 88% evidence Capital efficiency 15.4/25 · ROCE 16.6% · Operating margin 14% · 100% evidence Valuation 18.2/20 · P/E 12× · PEG 0.36 · 100% evidence Relative strength 8.2/20 · Lead over its industry n/a · Lead over NIFTY 500 -23% · 1 year -40.7% · 25% evidence · 0 of 12 weeks ahead Exact sum: 17.6 + 15.4 + 18.2 + 8.2 = 59.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Advance Agrolife Ltd](https://www.sectoralpha.in/stocks/advance-agrolife-ltd) ADVANCE · breaking out · Evidence leans up · 64% evidence 58.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.1/35 · Revenue 48.4% · Profit 81.5% · Operating margin change 1 points · 88% evidence Capital efficiency 14.1/25 · ROCE 19.6% · Operating margin 11% · 100% evidence Valuation 10.3/20 · P/E 16.3× · PEG n/a · 15% evidence Relative strength 12.4/20 · Lead over its industry n/a · Lead over NIFTY 500 10.6% · 1 year -8.6% · 25% evidence · 12 of 12 weeks ahead Exact sum: 22.1 + 14.1 + 10.3 + 12.4 = 58.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Dhanuka Agritech Ltd](https://www.sectoralpha.in/stocks/dhanuka-agritech-ltd) DHANUKA · turning · Evidence leans up · 100% evidence 57.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.8/35 · Revenue 0% · Profit 0.7% · Operating margin change 0 points · 100% evidence Capital efficiency 19.6/25 · ROCE 25.9% · Operating margin 23% · 100% evidence Valuation 9.2/20 · P/E 14.4× · PEG 2.27 · 100% evidence Relative strength 17.4/20 · Lead over its industry 7.1% · Lead over NIFTY 500 -2.8% · 1 year -28.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 10.8 + 19.6 + 9.2 + 17.4 = 57 · What this means: Relative strength against the index is -2.8%, and revenue and profit growth are weak. 9. [Jubilant Ingrevia Ltd](https://www.sectoralpha.in/stocks/jubilant-ingrevia-ltd) JUBLINGREA · quiet · Evidence leans up · 93% evidence 54.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.0/35 · Revenue 15.4% · Profit 21.9% · Operating margin change 3 points · 100% evidence Capital efficiency 13.6/25 · ROCE 11.4% · Operating margin 15% · 100% evidence Valuation 6.7/20 · P/E 24.7× · PEG 2.26 · 65% evidence Relative strength 8.4/20 · Lead over its industry -2.6% · Lead over NIFTY 500 -11.7% · 1 year -19.1% · 100% evidence · 3 of 12 weeks ahead Exact sum: 26 + 13.6 + 6.7 + 8.4 = 54.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Meghmani Organics Ltd](https://www.sectoralpha.in/stocks/meghmani-organics-ltd) MOL · breaking out · Evidence leans up · 64% evidence 52.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue -7.8% · Profit 100% · Operating margin change 7 points · 88% evidence Capital efficiency 9.5/25 · ROCE 6.7% · Operating margin 18% · 100% evidence Valuation 9.6/20 · P/E 20.8× · PEG n/a · 15% evidence Relative strength 11.0/20 · Lead over its industry n/a · Lead over NIFTY 500 -0.5% · 1 year -35% · 25% evidence · 11 of 12 weeks ahead Exact sum: 22 + 9.5 + 9.6 + 11 = 52.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [GSP Crop Science Ltd](https://www.sectoralpha.in/stocks/gsp-crop-science-ltd) GSPCROP · quiet · Too little evidence to rank firmly · 59% evidence 51.0 out of 100 Growth Capital Valuation Relative
12. [Epigral Ltd](https://www.sectoralpha.in/stocks/epigral-ltd) EPIGRAL · quiet · Evidence leans down · 81% evidence 49.6 out of 100 Growth Capital Valuation Relative
13. [Rallis India Ltd](https://www.sectoralpha.in/stocks/rallis-india-ltd) RALLIS · quiet · Evidence leans down · 85% evidence 48.4 out of 100 Growth Capital Valuation Relative
14. Bharat Rasayan Ltd this page BHARATRAS · quiet · Evidence leans down · 96% evidence 45.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.0/35 · Revenue -5.2% · Profit 3.6% · Operating margin change -3 points · 88% evidence Capital efficiency 15.3/25 · ROCE 16% · Operating margin 15% · 100% evidence Valuation 15.7/20 · P/E 10.6× · PEG 1.11 · 100% evidence Relative strength 4.3/20 · Lead over its industry -31% · Lead over NIFTY 500 -37.5% · 1 year -65.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 10 + 15.3 + 15.7 + 4.3 = 45.3 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 15. [Bhagiradha Chemicals & Industries Ltd](https://www.sectoralpha.in/stocks/bhagiradha-chemicals-industries-ltd) BHAGCHEM · quiet · Evidence leans down · 96% evidence 44.7 out of 100 Growth Capital Valuation Relative
16. [Shivalik Rasayan Ltd](https://www.sectoralpha.in/stocks/shivalik-rasayan-ltd) SHIVALIK · Evidence leans down · 63% evidence 43.9 out of 100 Growth Capital Valuation Relative
17. [Excel Industries Ltd](https://www.sectoralpha.in/stocks/excel-industries-ltd) EXCELINDUS · quiet · Evidence leans down · 64% evidence 42.7 out of 100 Growth Capital Valuation Relative
18. [NACL Industries Ltd](https://www.sectoralpha.in/stocks/nacl-industries-ltd) NACLIND · basing · Evidence leans down · 96% evidence 42.0 out of 100 Growth Capital Valuation Relative
19. [Best Agrolife Ltd](https://www.sectoralpha.in/stocks/best-agrolife-ltd) BESTAGRO · quiet · Evidence leans down · 90% evidence 42.0 out of 100 Growth Capital Valuation Relative
20. [Sumitomo Chemical India Ltd](https://www.sectoralpha.in/stocks/sumitomo-chemical-india-ltd) SUMICHEM · quiet · Evidence leans down · 85% evidence 41.7 out of 100 Growth Capital Valuation Relative
21. [UPL Ltd](https://www.sectoralpha.in/stocks/upl-ltd) UPL · basing · Evidence leans down · 71% evidence 41.5 out of 100 Growth Capital Valuation Relative
22. [Insecticides India Ltd](https://www.sectoralpha.in/stocks/insecticides-india-ltd) INSECTICID · quiet · Evidence leans down · 96% evidence 40.5 out of 100 Growth Capital Valuation Relative
23. [P I Industries Ltd](https://www.sectoralpha.in/stocks/p-i-industries-ltd) PIIND · quiet · Evidence leans down · 81% evidence 38.3 out of 100 Growth Capital Valuation Relative
24. [Astec Lifesciences Ltd](https://www.sectoralpha.in/stocks/astec-lifesciences-ltd) ASTEC · quiet · Most evidence points down · 71% evidence 32.7 out of 100 Growth Capital Valuation Relative
25. [Heranba Industries Ltd](https://www.sectoralpha.in/stocks/heranba-industries-ltd) HERANBA · quiet · Most evidence points down · 76% evidence 29.9 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pesticides/Agrochemicals](https://www.sectoralpha.in/sectors/pesticides-agrochemicals), all 25 compared on one page. ## Which companies are close to Bharat Rasayan in size? Bharat Rasayan is the 14th largest of 25 Pesticides/Agrochemicals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Bhagiradha Chemicals & Industries, GSP Crop Science and Titan Biotech. Just below it: Insecticides India, Meghmani Organics and India Pesticides. ### Pesticides/Agrochemicals companies close in size

1. [Bhagiradha Chemicals & Industries Ltd](https://www.sectoralpha.in/stocks/bhagiradha-chemicals-industries-ltd) ₹2,533 crore
2. [GSP Crop Science Ltd](https://www.sectoralpha.in/stocks/gsp-crop-science-ltd) ₹2,014 crore
3. [Titan Biotech Ltd](https://www.sectoralpha.in/stocks/titan-biotech-ltd) ₹1,755 crore
4. Bharat Rasayan Ltd ₹1,557 crore
5. [Insecticides India Ltd](https://www.sectoralpha.in/stocks/insecticides-india-ltd) ₹1,511 crore
6. [Meghmani Organics Ltd](https://www.sectoralpha.in/stocks/meghmani-organics-ltd) ₹1,339 crore
7. [India Pesticides Ltd](https://www.sectoralpha.in/stocks/india-pesticides-ltd) ₹1,297 crore

[All 25 Pesticides/Agrochemicals companies, largest first](https://www.sectoralpha.in/sectors/pesticides-agrochemicals#all-companies)

### Companies close in size in other industries

1. [NGL Fine Chem Ltd](https://www.sectoralpha.in/stocks/ngl-fine-chem-ltd) ₹1,561 crore · Pharma - Animal
2. [EMS Ltd](https://www.sectoralpha.in/stocks/ems-ltd) ₹1,560 crore · Infra - Engineering - General
3. Bharat Rasayan Ltd ₹1,557 crore
4. [Hinduja Global Solutions Ltd](https://www.sectoralpha.in/stocks/hinduja-global-solutions-ltd) ₹1,552 crore · IT Enabled Services
5. [Studds Accessories Ltd](https://www.sectoralpha.in/stocks/studds-accessories-ltd) ₹1,551 crore · Plastics - Others

## What else do people ask about Bharat Rasayan? ### What is Bharat Rasayan's share price today? Bharat Rasayan Ltd's share price is ₹950.95, −64.9% over the past year. The whole company is worth ₹1,580 Cr on the market. In the last 52 weeks it traded between ₹932 to ₹2,744; today it is 1% of the way up from the low, 33.9% below its 200-day average (as of 3 November 2026). ### What were Bharat Rasayan's latest quarterly results? Bharat Rasayan Ltd reported revenue of ₹338 Cr and net profit of ₹37.0 Cr for the Jun 2026 quarter. Revenue fell 10.3% and profit fell 7.5% compared with a year earlier. Earnings per share were ₹22.40. The operating margin was 15.0%, 3.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Bharat Rasayan's market cap? Bharat Rasayan Ltd's market capitalisation is ₹1,580 Cr at a share price of ₹950.95. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Bharat Rasayan performing? Bharat Rasayan Ltd's share price has been falling for 44 weeks. In its latest quarter, revenue fell 10.3% and profit fell 7.5% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 25 weeks running (as of 3 November 2026). ### Will Bharat Rasayan's share price go up? This page does not forecast Bharat Rasayan Ltd's share price. What it shows instead: the share price is ₹950.95, and it has been falling for 44 weeks. Its P/E of 10.8× is higher than 1% of its own last 6 years (as of 3 November 2026). ### Who owns Bharat Rasayan? Promoters own 75.0% of Bharat Rasayan Ltd, foreign institutions 0.6%, domestic institutions 1.7% and the public 22.7% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 3 November 2026). ### Does Bharat Rasayan have too much debt? No, Bharat Rasayan Ltd has little debt: its debt is 0.00× its equity, and its operating profit is 40 times its interest bill. FY26 borrowings were ₹1.0 Cr against equity of ₹1,274 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Bharat Rasayan in its business cycle? Bharat Rasayan Ltd's FY26 operating margin was 16.0%, against a 8-year range of 11.0% to 22.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 15.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Bharat Rasayan story? The main question: yearly earnings per share moved +3.3% while the share price moved −64.9%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Bharat Rasayan a stock worth studying right now? What the numbers show: Bharat Rasayan Ltd's P/E is near the low end of its own history, higher than only 1% of past readings, and its quarterly results are still getting worse. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- 52 week high & low: https://www.sectoralpha.in/52-week-high-stocks-india

This is research, not advice. We’re not SEBI-registered.